Form 4: Cue Biopharma SVP, General Counsel Colin Sandercock Reports Stock Option Grant

Colin Sandercock, SVP and General Counsel of Cue Biopharma, Inc., reports the acquisition of stock options.

Summary

• Colin Sandercock, the SVP and General Counsel of Cue Biopharma, Inc., filed a Form 4 on March 25, 2025, reporting a transaction.
• On March 21, 2025, Sandercock acquired stock options for 200,000 shares of Cue Biopharma's common stock at an exercise price of $0.99 per share.
• The options become exercisable in eight equal semi-annual installments starting September 21, 2025, and expire on March 20, 2035.
• Following the reported transaction, Sandercock directly owns derivative securities for 200,000 shares.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock option grants, which is a standard practice. It indicates confidence in the company's future, but it's not overwhelmingly positive.

Positives

• The granting of stock options to a key executive like the SVP and General Counsel can be seen as an incentive to align their interests with the company's long-term success.

Industry Context

Stock option grants are a common practice in the biopharmaceutical industry to incentivize executives and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• The vesting schedule of semi-annual installments is fairly typical.
• The exercise price is likely based on the current market price of CUE stock at the time of the grant.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised in the future.

Key Dates

Keywords

Form 4, Stock Options, Beneficial Ownership, Cue Biopharma, Sandercock, CUE